Tim Collard | Chief Executive Officer
Pacific GeneTech Limited | Hong Kong

Tim Collard, Chief Executive Officer, Pacific GeneTech Limited

Tim Collard is the Chief Executive Officer of Pacific GeneTech and is responsible for the overall management and operations of the company. Tim has more than 40 years’ experience in the pharmaceutical and biotechnology industries globally. He started his career with Connaught Laboratories supplying human vaccines to the Hong Kong government and establishing the business to supply poultry vaccines for Hong Kong farmers. He then joined Califas, a China-based consultancy, where he negotiated the first Sino-US joint manufacturing contract in the Chinese healthcare industry. Next, Tim joined Solvay as Far East Director for Solvay’s Biochem Products division, a joint venture with the Pasteur Institute which developed human health products and agricultural insecticides. In 1987 he became General Manager, Far East, of British biopharmaceuticals company Porton International where he established marketing, distribution, and local R&D in Asia.

In 1993, Tim served as Vice President of Lotus Healthcare Corporation, a manufacturer of oral controlled-release morphine and other medicinal narcotics in China. He was responsible for business development, sourcing of Chinese pharmaceutical raw materials, and all in-licensing and technology transfer. In 1997, he established Phoenix Lifesciences and later, associate company Phoenix Innovation to provide transactional consultancy services to the pharmaceutical, life science, and high technology sectors in Greater China and Southeast Asia. In this consulting capacity, Tim negotiated a “first mover” supply agreement for bulk antibiotics between a Chinese producer and British veterinary pharmaceutical companies. Tim continued to work on a variety of projects with local and multinational companies including AstraZeneca, Authentix, Aventis, bioMérieux, Proctor & Gamble, SciClone, and Xenova.

Tim holds a BA in biology from Bristol University, United Kingdom.


Phar-East Day Two @ 11:10

Low cost, flexible universal adjuvant & delivery system to orally deliver PGT and third party inactivated vaccines for infectious diseases

  •     Traditional vs new generation vaccines to protect against infectious diseases
  •     Building effective vaccines against genetic shifts and the appearance of mutated strains
  •     Moving beyond animal vaccines: How PGT platforms are being developed for human usage

back to speakers